Brokerages Expect GlycoMimetics Inc (GLYC) to Post -$0.26 EPS

Wall Street analysts expect GlycoMimetics Inc (NASDAQ:GLYC) to report earnings of ($0.26) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for GlycoMimetics’ earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.27). GlycoMimetics posted earnings of ($0.36) per share in the same quarter last year, which would suggest a positive year over year growth rate of 27.8%. The firm is expected to announce its next quarterly earnings report on Wednesday, March 7th.

On average, analysts expect that GlycoMimetics will report full-year earnings of ($1.12) per share for the current year, with EPS estimates ranging from ($1.15) to ($1.11). For the next fiscal year, analysts forecast that the company will report earnings of ($0.86) per share, with EPS estimates ranging from ($1.73) to $0.34. Zacks’ EPS calculations are an average based on a survey of analysts that that provide coverage for GlycoMimetics.

How to Become a New Pot Stock Millionaire

GLYC has been the topic of a number of research reports. BidaskClub raised GlycoMimetics from a “sell” rating to a “hold” rating in a report on Wednesday, December 6th. Zacks Investment Research lowered GlycoMimetics from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. SunTrust Banks raised their price target on GlycoMimetics to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 12th. Roth Capital initiated coverage on GlycoMimetics in a report on Monday, October 23rd. They set a “buy” rating and a $25.00 price target on the stock. Finally, Cowen reissued a “buy” rating on shares of GlycoMimetics in a report on Wednesday, December 6th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $22.67.

In other GlycoMimetics news, SVP Helen M. Thackray sold 2,000 shares of GlycoMimetics stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $15.01, for a total value of $30,020.00. Following the sale, the senior vice president now owns 148,615 shares of the company’s stock, valued at approximately $2,230,711.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 43.80% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in GLYC. FMR LLC purchased a new stake in GlycoMimetics in the 2nd quarter valued at approximately $16,780,000. Redmile Group LLC boosted its holdings in GlycoMimetics by 59.0% in the 4th quarter. Redmile Group LLC now owns 1,930,668 shares of the biotechnology company’s stock valued at $32,416,000 after purchasing an additional 716,580 shares in the last quarter. AXA purchased a new stake in GlycoMimetics in the 4th quarter valued at approximately $8,579,000. Janus Henderson Group PLC purchased a new stake in GlycoMimetics in the 2nd quarter valued at approximately $5,598,000. Finally, BlackRock Inc. boosted its holdings in GlycoMimetics by 89.1% in the 4th quarter. BlackRock Inc. now owns 991,948 shares of the biotechnology company’s stock valued at $16,655,000 after purchasing an additional 467,338 shares in the last quarter. 97.44% of the stock is currently owned by institutional investors.

Shares of GlycoMimetics (NASDAQ GLYC) opened at $25.01 on Tuesday. GlycoMimetics has a 52-week low of $3.82 and a 52-week high of $26.05. The company has a market capitalization of $858.79, a PE ratio of -20.17 and a beta of 3.40.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2018/02/20/brokerages-expect-glycomimetics-inc-glyc-to-post-0-26-eps.html.

GlycoMimetics Company Profile

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Get a free copy of the Zacks research report on GlycoMimetics (GLYC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit